Signos CEO Sharam Fouladgar-Mercer joins 'Fast Money' to talk first FDA-approved glucose monitor for weight loss.
Breakdown
- Cygnos receives FDA approval for its glucose monitoring system for weight loss. 6s
- The wearable device provides real-time metabolic data to users via a smartphone app. 1m 13s
- The system costs $129 per month and is FSA, HSA eligible, with insurer reimbursement being explored. 1m 48s
- Cygnos is positioned as a complementary solution to GLP-1 drugs and aims to be accessible for a broad range of users. 2m 5s
- The device integrates with other smart health devices and uses AI to predict metabolic outcomes. 4m 4s